Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue tetravalent vaccine, live attenuated + measles, mumps and rubella vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This combination refers to the concomitant administration of a live-attenuated tetravalent dengue vaccine and a trivalent measles, mumps, and rubella (MMR) vaccine. The dengue component, such as Takeda's TAK-003 (Qdenga) or Sanofi's CYD-TDV (Dengvaxia), is designed to provide broad protection against all four dengue virus serotypes (DENV-1, -2, -3, and -4). TAK-003 specifically utilizes a dengue serotype 2 genetic backbone to express surface antigens for all four serotypes. The MMR component is a standard trivalent vaccine containing attenuated strains of measles, mumps, and rubella viruses. Clinical studies, such as Takeda's DEN-305 trial, have evaluated the safety and immunogenicity of co-administering these vaccines to facilitate integrated pediatric immunization schedules in dengue-endemic regions, ensuring that simultaneous delivery does not result in significant immune interference.
- Brand names
- PriorixM-M-R II
- Other names
- Dengue vaccine + MMR vaccineTAK-003 + MMRCYD-TDV + MMR
Beyond the preview
Go deeper on dengue tetravalent vaccine, live attenuated + measles, mumps and rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue tetravalent vaccine, live attenuated + measles, mumps and rubella vaccine.